Lyrica

FDA Approves New Treatment for Diabetic Peripheral Neuropathy, Postherpetic Neuralgia

FDA Approves New Treatment for Diabetic Peripheral Neuropathy, Postherpetic Neuralgia

By

The FDA has approved Lyrica CR, a once-daily treatment for the management of neuropathic pain associated with diabetic peripheral neuropathy and the management of postherpetic neuralgia.

Sign Up for Free e-Newsletters